The application discloses application of isoprenyl
cysteine carboxymethyltransferase as a
rheumatoid arthritis treatment target in preparation of a
rheumatoid arthritis treatment
drug. The application finds that the expression of ICMT is down-regulated after NSUN2 is knocked out, further research on the expression level of ICMT in RA FLS finds that the mRNA and
protein expression of RA FLS ICMT is obviously up-regulated, the
cell migration and invasion ability is reduced after ICMT is knocked down, and the expression of MMPs such as MMP1, MMP3 and MMP9 of RA FLS is obviously inhibited. The above results show that ICMT can regulate the abnormal migration and invasion of RA FLS, and targeting ICMT can become a new means to prevent RA
joint destruction. Therefore, the application provides an
effective treatment target for RA, and provides a new idea for
clinical treatment of RA.